Greenwich LifeSciences, Inc. (NASDAQ: GLSI) announced that the FDA granted Fast Track designation for GLSI-100, the company's immunotherapy designed to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE